09:15 AM EDT, 08/08/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) reported a Q2 net loss Thursday of $1.52 per diluted share, widening from a loss of $1.40 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.23.

Collaboration revenue for the quarter ended June 30 was $7 million, down from $13.6 million a year earlier.

Analysts surveyed by Capital IQ expected $18.3 million.

As of June 30, the company said it had cash, cash equivalents and marketable securities of $939.9 million, anticipated to finance operations into late 2026.

Price: 21.50, Change: +0.19, Percent Change: +0.89